Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Insmed ( (INSM) ) has provided an update.
On April 7, 2026, Insmed reported topline results from its Phase 2b CEDAR trial of brensocatib in adults with moderate to severe hidradenitis suppurativa, showing the study failed to meet primary and secondary efficacy endpoints at both 10 mg and 40 mg doses. Despite brensocatib demonstrating a favorable safety profile with no new safety signals, patients on active treatment saw smaller reductions in abscess and inflammatory nodule counts than those on placebo over 16 weeks.
The randomized, double-blind, placebo-controlled study enrolled 214 patients at 72 sites globally, and the lack of efficacy in this proof-of-concept trial led Insmed to halt further development of brensocatib for hidradenitis suppurativa. The setback narrows the company’s pipeline in dermatology but preserves brensocatib’s safety record for potential use in other indications, while Insmed plans to present the data at a future medical congress, offering insights for the broader HS research community.
The most recent analyst rating on (INSM) stock is a Buy with a $181.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
The score is held back primarily by very large ongoing losses and cash burn, plus weak technical momentum. Offsetting these, management’s bullish 2026 guidance and strong commercial execution signals, along with positive ENCORE results that may expand ARIKAYCE’s market, provide meaningful upside catalysts despite valuation being constrained by current unprofitability.
To see Spark’s full report on INSM stock, click here.
More about Insmed
Insmed Incorporated is a global biopharmaceutical company focused on developing first- and best-in-class therapies for patients with serious diseases, with a particular emphasis on pulmonary and inflammatory conditions. Headquartered in Bridgewater, N.J., the company markets two approved treatments for chronic lung diseases and advances a diversified pipeline, including gene therapy and AI-driven protein engineering programs.
Insmed operates research and office locations across the U.S., Europe and Japan, targeting patient communities with high unmet medical need. Its early-stage work spans multiple modalities, such as RNA technologies and synthetic rescue, underscoring a strategy to build a broad platform in serious, often rare, conditions rather than relying on a single asset or therapeutic area.
Average Trading Volume: 2,576,170
Technical Sentiment Signal: Buy
Current Market Cap: $35.31B
Find detailed analytics on INSM stock on TipRanks’ Stock Analysis page.